Representative image
NEW DELHI: The Union government has informed the Supreme Court that vaccine production in India will be ramped up to more than 13 crore doses per month by the end of July while negating the court’s suggestions for door-to-door vaccination under the national immunisation scheme as unsuitable for Covid-19 inoculation.
“Production capacity of vaccines under the vaccination drive has been gradually ramped up and is expected to increase further in the next couple of months. Serum Institute of India has ramped up production from 5 crore doses per month to 6.5 crore doses per month and further ramp-up is expected by July. Bharat Biotech has increased production from 90 lakh/month to 2 crore doses/month and further increase is expected up to 5.5 crore doses/month by July. Sputnik V (distributed by Dr Reddy’s Laboratories) is expected to increase production from 30 lakh to 1.2 crore doses/month by July,” the government said.
Domestic COVID-19 Vaccine Production To Surge To Over 13 Crore Doses Per Month By July End: Govt To Supreme Court
Supreme Court of India (Sonu Mehta/Hindustan Times via Getty Images)
The government has informed the Supreme Court that by the end of July, production of COVID-19 vaccines in India will be ramped up to more than 13 crore doses per month, reports
Times of India.
The government said that Pune based Serum Institute of India (SII) has ramped up its production of Covishield from five crore doses per month to 6.5 crore doses per month. It added that further ramp-up is expected by July.
PM asks vaccine companies to ramp up production, assures logistical support
SECTIONS
Last Updated: Apr 21, 2021, 07:48 AM IST
Share
Synopsis
In May 2020, Modi had directed officials not to differentiate between the public and private sectors and said the government should work as investor, incubator, evaluator and buyer of vaccines.
On Tuesday, the Prime Minister praised the efforts of vaccine manufacturers in developing vaccines in record time and producing them on a large scale to meet the requirement in India and for export to some countries.
Prime Minister Narendra Modi asked vaccine manufacturers to step up production to meet increasing demand a day after the government said all people 18 and above will be eligible for Covid jabs from May 1. He assured companies that the Centre will provide logistical support, including speedy and scientific approvals.
Haffkine Institute gets Centre’s nod to manufacture Covaxin
April 16, 2021
×
The central government has given permission to the Haffkine Institute to manufacture Covaxin, an anti-coronavirus vaccine of Bharat Biotech.
“ The central government’s Science and Technology Department has given permission to manufacture Covaxin with the transfer of technology from Bharat Biotech. Chief Minister Uddhav Thackeray has thanked Prime Minister Narendra Modi for accepting his request and issuing the permission” CM Office tweeted at 11.27 pm on Thursday.
The Dept of Science & Technology, Government of India, has granted approval to Haffkine Institute to produce Bharat Biotech s Covaxin vaccine on a transfer of technology basis. CM Uddhav Balasaheb Thackeray has thanked the Hon’ble PM Shri @narendramodi for approving this request. CMO Maharashtra (@CMOMaharashtra) April 15, 2021
File photo for representation
MUMBAI: The Maharashtra government on Wednesday raised a demand with Prime Minister Narendra Modi to allow the state to manufacture the indegious vaccine, Covaxin developed by Bharat Biotech at Mumbai s Haffkine Institute.
Maharashtra chief minister Uddhav Thackeray raised the issue in the PM s Covid19 review meet on Wednesday. Thackeray sought for a technology transfer under the Mission Covid security from Bharat biotech to Haffkine Biopharmaceutical Corporation limited one of the country s oldest and premier biomedical research facilities. If the technology transfer happens, either vaccine can be produced at Haffkine or they can work on a fill and finish arrangement. Nearly 126 million doses can be manufactured at the Haffkine facility, said Thackeray.